Cellular Therapy Using Epitope-Imprinted Composite Nanoparticles to Remove α-Synuclein from an In Vitro Model

Cellular Therapy Using Epitope-Imprinted Composite Nanoparticles to Remove α-Synuclein from an In Vitro Model

Several degenerative disorders of the central nervous system, including Parkinson’s disease (PD), are related to the pathological aggregation of proteins. Antibodies against toxic disease proteins, such as α-synuclein (SNCA), are therefore being developed as possible therapeutics. In this work, one...

Full description

Bibliographic Details
Main Authors: Mei-Hwa Lee, Jeng-Shiung Jan, James L. Thomas, Yuan-Pin Shih, Jin-An Li, Chien-Yu Lin, Tooru Ooya, Lilla Barna, Mária Mészáros, András Harazin, Gergő Porkoláb, Szilvia Veszelka, Maria A. Deli, Hung-Yin Lin
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Cells
Subjects:
α-synuclein
peptide imprinting
magnetic nanoparticles
gene activation
protein extraction
Online Access:https://www.mdpi.com/2073-4409/11/16/2584
Description
Summary:Several degenerative disorders of the central nervous system, including Parkinson’s disease (PD), are related to the pathological aggregation of proteins. Antibodies against toxic disease proteins, such as α-synuclein (SNCA), are therefore being developed as possible therapeutics. In this work, one peptide (YVGSKTKEGVVHGVA) from SNCA was used as the epitope to construct magnetic molecularly imprinted composite nanoparticles (MMIPs). These composite nanoparticles were characterized by dynamic light scattering (DLS), high-performance liquid chromatography (HPLC), isothermal titration calorimetry (ITC), Brunauer–Emmett–Teller (BET) analysis, and superconducting quantum interference device (SQUID) analysis. Finally, the viability of brain endothelial cells that were treated with MMIPs was measured, and the extraction of SNCA from CRISPR/dCas9a-activated HEK293T cells from the in vitro model system was demonstrated for the therapeutic application of MMIPs.
ISSN:2073-4409

Similar Items